Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Moodys
UBS
Cerilliant
Citi
QuintilesIMS
Teva
Merck
McKesson

Generated: October 16, 2018

DrugPatentWatch Database Preview

BEPREVE Drug Profile

« Back to Dashboard

When do Bepreve patents expire, and what generic alternatives are available?

Bepreve is a drug marketed by Bausch And Lomb Inc and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in BEPREVE is bepotastine besilate. There are seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the bepotastine besilate profile page.

Drug patent expirations by year for BEPREVE
Generic Entry Opportunity Date for BEPREVE
Generic Entry Date for BEPREVE*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION/DROPS;OPHTHALMIC

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for BEPREVE
Synonyms for BEPREVE
(+)-(S)-4-(4-((4-Chlorophenyl)(2-pyridyl)methoxy)piperidino)butyric acid monobenzenesulfonate
(+)-(S)-4-[4-[1-(4-Chlorophenyl)-1-(2-pyridyl)methoxy]piperidin-1-yl]butyric acid benzenesulfonate
(S)-4-(4-((4-chlorophenyl)(pyridin-2-yl)methoxy)piperidin-1-yl)butanoic acid compound with benzenesulfonic acid (1:1)
(S)-4-[4-(4-Chlorophenyl-2-pyridylmethoxy)piperidinyl]butyric Acid Benzenesulfonate
(s)-4-[4-[(4-chlorophenyl)(2-pyridyl)-methoxy]piperidino]butanoic acid monobenzenesulfonic acid salt
(s)-4-[4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidino]butanoic acid monobenzenesulfonic acid salt
1-Piperidinebutanoic acid, 4-((4-chlorophenyl)-2-pyridinylmethoxy)- (S)-, monobenzenesulfonate
1-piperidinebutanoic acid, 4-[(4-chlorophenyl)-2-pyridinylmethoxy]-, (s)-, monobenzenesulfonate
1-piperidinebutanoic acid, 4-[(s)-(4-chlorophenyl)-2-pyridinylmethoxy]-, monobenzenesulfonate
190786-44-8
4-((4-Chlorophenyl)-2-pyridinylmethoxy)- (S)-1-piperidinebutanoic acid monobenzenesulfonate
4-[(S)-(4-Chlorophenyl)-2-pyridinylmethoxy]-1-piperidinebutanoic Acid Benzenesulfonate
4-[4-[(r)-(4-chlorophenyl)-pyridin-2-yl-methoxy]-1-piperidyl]butanoic acid
4-{4-[(s)-(4-chlorophenyl)(pyridin-2-yl)methoxy]piperidin-1-yl}butanoic acid benzenesulfonate
6W18MO1QR3
786B448
ABP001064
AC-24015
AC1L4UXJ
AC1Q6WSY
AK322015
AKOS025401655
AN-5247
API0001668
AS-17863
BC214879
benzenesulfonic acid; 4-[4-[(S)-(4-chlorophenyl)-(2-pyridyl)methoxy]-1-piperidyl]butanoic acid
benzenesulfonic acid; 4-[4-[(S)-(4-chlorophenyl)-pyridin-2-ylmethoxy]piperidin-1-yl]butanoic acid
benzenesulfonic acid;4-[4-[(S)-(4-chlorophenyl)-pyridin-2-ylmethoxy]piperidin-1-yl]butanoic acid
Bepomax
Bepotastine (Beslilate)
Bepotastine benzenesulfonate
Bepotastine Benzenesulfonate Salt
Bepotastine besilate
Bepotastine besilate (JP17)
Bepotastine Besitate
Bepotastine Beslilat
Bepotastine besylate
Bepotastine besylate (USAN)
Bepotastine besylate [USAN]
Bepreve (TN)
Betotastine besilate
C27H31ClN2O6S
CB0259
CHEBI:31281
CHEMBL1201759
CS-0383
CTK4E0497
D01654
DTXSID80172577
FT-0655883
HY-A0015
J-012325
KS-00000FR0
LS-114358
MFCD01938491
MolPort-005-938-034
PubChem19122
s3037
SC-47417
SCHEMBL1287638
Talion
Talion (TN)
TAU-284
tau284
UDGHXQPQKQPSBB-BOXHHOBZSA-N
UNII-6W18MO1QR3
V2224
W-5279

US Patents and Regulatory Information for BEPREVE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bausch And Lomb Inc BEPREVE bepotastine besilate SOLUTION/DROPS;OPHTHALMIC 022288-001 Sep 8, 2009 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Bausch And Lomb Inc BEPREVE bepotastine besilate SOLUTION/DROPS;OPHTHALMIC 022288-001 Sep 8, 2009 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Bausch And Lomb Inc BEPREVE bepotastine besilate SOLUTION/DROPS;OPHTHALMIC 022288-001 Sep 8, 2009 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for BEPREVE
Drugname Dosage Strength RLD Date
➤ Subscribe Ophthalmic Solution 1.5% ➤ Subscribe ➤ Try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Moodys
UBS
Cerilliant
Citi
QuintilesIMS
Teva
Merck
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.